Pbf Energy Incorporated (NYSE:PBF) had an increase of 7.34% in short interest. PBF’s SI was 13.25 million shares in February as released by FINRA. Its up 7.34% from 12.34 million shares previously. With 2.01M avg volume, 7 days are for Pbf Energy Incorporated (NYSE:PBF)’s short sellers to cover PBF’s short positions. The SI to Pbf Energy Incorporated’s float is 14.26%. The stock increased 0.72% or $0.21 during the last trading session, reaching $29.21. About 2.15 million shares traded or 4.39% up from the average. PBF Energy Inc. (NYSE:PBF) has declined 20.84% since February 10, 2017 and is downtrending. It has underperformed by 37.54% the S&P500.
Analysts expect Seres Therapeutics, Inc. (NASDAQ:MCRB) to report $-0.73 EPS on March, 15.They anticipate $0.10 EPS change or 15.87% from last quarter’s $-0.63 EPS. After having $-0.17 EPS previously, Seres Therapeutics, Inc.’s analysts see 329.41% EPS growth. The stock decreased 1.52% or $0.13 during the last trading session, reaching $8.45. About 306,044 shares traded or 86.83% up from the average. Seres Therapeutics, Inc. (NASDAQ:MCRB) has declined 64.58% since February 10, 2017 and is downtrending. It has underperformed by 81.28% the S&P500.
Among 16 analysts covering PBF Energy Inc (NYSE:PBF), 5 have Buy rating, 4 Sell and 7 Hold. Therefore 31% are positive. PBF Energy Inc had 60 analyst reports since July 24, 2015 according to SRatingsIntel. The stock of PBF Energy Inc. (NYSE:PBF) earned “Hold” rating by RBC Capital Markets on Wednesday, October 18. RBC Capital Markets maintained PBF Energy Inc. (NYSE:PBF) rating on Thursday, July 20. RBC Capital Markets has “Hold” rating and $2300 target. Citigroup maintained PBF Energy Inc. (NYSE:PBF) on Monday, July 17 with “Buy” rating. J.P. Morgan downgraded the stock to “Sell” rating in Tuesday, December 12 report. Cowen & Co maintained it with “Buy” rating and $30.0 target in Tuesday, October 17 report. The stock of PBF Energy Inc. (NYSE:PBF) earned “Neutral” rating by Goldman Sachs on Wednesday, April 5. The stock of PBF Energy Inc. (NYSE:PBF) has “Buy” rating given on Wednesday, January 24 by Citigroup. RBC Capital Markets maintained it with “Hold” rating and $2200 target in Thursday, July 6 report. As per Tuesday, October 24, the company rating was downgraded by Macquarie Research. The firm has “Hold” rating by Tudor Pickering given on Friday, September 1.
Investors sentiment decreased to 0.84 in 2017 Q3. Its down 1.10, from 1.94 in 2017Q2. It is negative, as 32 investors sold PBF Energy Inc. shares while 82 reduced holdings. 30 funds opened positions while 66 raised stakes. 116.04 million shares or 2.69% less from 119.24 million shares in 2017Q2 were reported. Blackrock holds 0.01% of its portfolio in PBF Energy Inc. (NYSE:PBF) for 9.03M shares. Hartford Inv Management holds 0.04% or 82,200 shares in its portfolio. First Heartland Consultants, Missouri-based fund reported 49,352 shares. Citigroup holds 0% or 46,883 shares in its portfolio. Knightsbridge Asset Mngmt Limited Liability reported 335,899 shares. Ims Cap Mgmt owns 8,850 shares for 0.16% of their portfolio. Weaver C Barksdale & Assocs has 0.12% invested in PBF Energy Inc. (NYSE:PBF). Parkside Comml Bank And Trust invested in 0% or 23 shares. National Bank & Trust Of Ny Mellon Corporation reported 2.02M shares. 9,080 were reported by Teacher Retirement Systems Of Texas. Indexiq Advsr Ltd Liability Corporation holds 0% of its portfolio in PBF Energy Inc. (NYSE:PBF) for 2,864 shares. Creative Planning stated it has 7,917 shares or 0% of all its holdings. Roundview Capital Lc invested in 0.21% or 32,715 shares. Northwest Invest Counselors Lc stated it has 2,500 shares. Canada Pension Plan Investment Board has 0% invested in PBF Energy Inc. (NYSE:PBF).
PBF Energy Inc., together with its subsidiaries, engages in the refining and supply of petroleum products. The company has market cap of $3.33 billion. The firm operates through two divisions, Refining and Logistics. It has a 13.82 P/E ratio. It produces gasoline, ultra-low-sulfur diesel, heating oil, diesel fuel, jet fuel, lubricants, petrochemicals, and asphalt, as well as unbranded transportation fuels, petrochemical feedstocks, blending components, and other petroleum products.
Seres Therapeutics, Inc., a microbiome therapeutics platform company, engages in developing biological drugs designed to restore health by repairing the function of a dysbiotic microbiome. The company has market cap of $342.48 million. The Company’s lead product candidate is SER-109, a bacterial spore ecology, which has completed Phase II clinical study to treat multiply recurrent Clostridium difficile infection . It currently has negative earnings. The firm also develops SER-287 that is in Phase Ib clinical study in patients with mild-to-moderate ulcerative colitis; and SER-262, a synthetic microbiome therapeutic candidate, which is in Phase Ib study in patients with primary CDI.